The Oxford London Lecture aims to connect the widest possible audience to Oxford's ground-breaking research. This year, Adrian Hill, Director of the Jenner Institute, will discuss the dilemma facing public health officials, vaccine companies and academic vaccine developers during the Ebola outbreak in late 2014 and the remarkable rapid response that ensued.
The lecture will be followed by a panel discussion with Alice Thomson (The Times columnist), Nicola Blackwood (MP), Johan Van Hoof (Crucell), and Prof Chris Whitty (London School of Tropical Hygiene and Medicine).
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.
Dr Irina Redchenko, a senior investigator on the trial from the Jenner Institute explained: ‘Cancers can spread in the body is because the immune system does not recognise the cancer cells as foreign and so does not attack them. The right type of vaccine could help the body to attack and destroy the cancer cells.’
Applications are now open for a new MRC 'Confidence in Concept' fund, managed by The Tropical Infectious Disease Consortium. The fund of £500,000 is aimed at projects that translate scientific discoveries into therapeutics, diagnostics and vaccine development.
The partners of the Consortium are London School of Hygiene and Tropical Medicine, Liverpool School of Medicine, The Jenner Institute at the University of Oxford, and Public Health England Microbiology Research Services, who will provide awards of up to £50,000 via an open, competitive and peer-reviewed process (deadline 30th April 2016).
Tuesday 1st March 2016, 17:30 – 18:30
Oxford Sciences Innovation plc is a £320m partnership between the University of Oxford and Isis Innovation to find the most ground-breaking ideas coming out of Oxford and develop them into market-leading companies.
Audience: Oxford researchers and DPhil students
Venue: Lecture Auditorium, Christ Church, St Aldates, Oxford OX1 1DP
Canapes and drinks from 18:30 onwards at The House Cocktail Bar, Wheatsheaf Yard, 11 Blue Boar St, Oxford OX1 4EE.
To secure your place, please email email@example.com.
To read more: http://www.oxfordsciencesinnovation.com/
A research team led by a Kenyan scientist has produced the first Rift Valley Fever (RVF) vaccine that can be used by both humans and animals. In a study published this week in Scientific Reports, an online journal, the researchers demonstrated that a single injection with this vaccine is safe and offers complete protection against RVF in livestock and recommends that the vaccine be tried in humans.
Outbreak: Lessons from Ebola. On 6 December 2013 a two-year-old boy called Emile Ouamouno died of a serious illness in a small village in Guinea. A month later Emile’s three-year-old sister, his mother and grandmother were all dead. This was the start of an Ebola epidemic that swept through West Africa in 2014, killing over 11,000 people and infecting nearly 30,000.
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Applications are now open for the prestigious Wellcome Trust funded 4 year PhD programme in Infection, Immunology and Translational Medicine.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.